品名：Seraseq® ctDNA MRD Panel Mix

货号：0710-2146

品牌：SeraCare 

Product Specifications - ctDNA MRD Panel Mix 

# of Variants：>600 

Tumor Levels：0%, 0.5%, 0.05% & 0.005% 

 # of vials/kit：4 

Fill Volume：20 µl 

Concentration：10 ng/µl 

Total Mass：4 x 200 ng 

Format：Purified DNA in buffer (Tris/EDTA) 

Details

INTRODUCTION 

MRD monitoring typically involves measuring signs of a cancer in order to determine if it is disappearing 

(progression) or returning (relapse). Typically, this can be facilitated by use of less invasive techniques such 

as liquid biopsy (ctDNA), to monitor cancer-specific somatic variants. A patient-derived approach to the 

application of ctDNA-based MRD monitoring starts with a tumor profiling analysis to identify clinically 

relevant tumor variants that constitute the patient’s genomic profile. Following this, a targeted panel/

assay containing a subset of the gene variants can be designed for disease monitoring by detecting 

presence or absence of circulating tumor (ct)DNA variants in the patient’s blood sample. These 

patient-derived MRD analyses represent a paradigm shift in disease monitoring, and have been adopted 

by leading liquid biopsy NGS vendors such as Natera’s Signatera® platform and Archer/Invitae’s 

Personalized Cancer Monitoring (PCM) assay. 

LGC SeraCare has developed a novel ctDNA MRD mutation mix panel designed to support the development, 

validation and clinical deployment of ctDNA-based patient-derived MRD monitoring NGS assays. The new 

Seraseq ctDNA MRD Panel Mix product is constructed from combination of a diseased human cell line, 

its SNP-matched normal cell line, and biosynthetic DNA containing variants commonly targeted by therapeutic 

drugs (see list below). The blended DNA is fragmented, sized to mimic ctDNA fragment sizes, and serially diluted 

to tumor fractions (TF) of 0%, 0.5%, 0.05% and 0.005%. 

 FEATURES AND BENEFITS 

   Combination of diseased human cancer cell line, its SNP-matched normal and biosynthetic DNA variants. 

   Fragmented, sized (ctDNA), and blended at four tumor levels: 0% (WT), 0.5%, 0.05% and 0.005%. 

   Develop, validate and routinely determine presence/absence of patient-derived disease variants with high 

precision (against a matched normal (WT) background). 

  Variant detection and VAF analysis by digital PCR and targeted cfDNA NGS assay. 

  Available as a purified DNA mix ready for targeted sequencing library prep. 

  Manufactured in GMP-compliant and ISO 13485-certified facilities.

维百奥生物代理SeraCare对照及参比物质。

维百奥（北京）生物科技有限公司，自2018年与SeraCare（现隶属于LGC Clinical Diagnostics）合作以来，长期为中国客户

提供包括SeraSeq系列参比物质，领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质，可以用于任何

研发阶段，以确保临床基因组学检测结果的准确性。

SeraCare参比物质涵盖的范围：

1）Next Generation Sequencing

2）Sanger Sequencing

3）Real-time PCR and digital PCR (dPCR)

4）Microarray

主要特点

1）Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, 

and RNA fusions

2）Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs

3）Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA 

in plasma, and FFPE

4）Manufactured in cGMP-compliant, ISO 13485-certified facilities

5）Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers